Axel Hoos

Axel Hoos

Chairman at
Cancer Research Institute
56 year
Health Technology
Commercial Services
Health Services

Profile

Axel Hoos was the founder of Imugene Ltd. (founded in 2013) and held the title of Independent Non-Executive Director.
He is currently the Co-Chairman at Cancer Research Institute, Director at Nextpoint Therapeutics, Inc. (since 2023), and Trustee at Albert B. Sabin Vaccine Institute, Inc. Dr. Hoos has previously served as the Chief Executive Officer & Director at Scorpion Therapeutics, Inc. (2021-2024), Senior Director-Clinical Development at Agenus, Inc. (2001-2005), Independent Director at TCR2 Therapeutics, Inc. (2020-2023), and Global Medical Lead-Immunology & Oncology at Bristol Myers Squibb Co. (2005-2011).
He has also held the position of Senior VP & Therapeutic Area Head-Oncology at GlaxoSmithKline Pharmaceuticals Ltd. Dr. Hoos obtained his doctorate degree from Ruprecht-Karls-Universität Heidelberg in 1997.

Axel Hoos active positions

CompaniesPositionStart
Director/Board Member -
Chairman -
Director/Board Member 21/03/2023

Former positions of Axel Hoos

CompaniesPositionEnd
Chief Executive Officer 04/01/2024
TCR2 THERAPEUTICS INC. Director/Board Member 01/06/2023
IMUGENE LIMITED Founder 19/11/2021
BRISTOL-MYERS SQUIBB COMPANY Corporate Officer/Principal 01/01/2011
AGENUS INC. Corporate Officer/Principal 01/01/2005
See the detail of Axel Hoos's experience

Training of Axel Hoos

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

Connections

80

1st degree connections

10

1st degree companies

Male

Female

Members of the board

Executives

Linked companies

Private companies10

Health Technology

Health Technology

Commercial Services

Health Technology

Health Technology

Health Services

Consumer Services

Health Technology

Health Technology

Commercial Services